Scientific Programs Office, Code 01A, Naval Health Research Center, San Diego, CA 92106, U.S.A.
Anticancer Res. 2014 Mar;34(3):1163-6.
BACKGROUND/AIM: To determine whether higher serum 25-hydroxyvitamin D [25(OH)D] at diagnosis is associated with longer survival of patients with breast cancer.
A meta-analysis was performed of five studies of the relationship between 25(OH)D and mortality from breast cancer. A pooled hazard ratio was calculated using a random-effects model. The Der Simonian-Laird test was used to assess homogeneity.
Higher serum concentrations of 25(OH)D were associated with lower case-fatality rates after diagnosis of breast cancer. Specifically, patients in the highest quintile of 25(OH)D had approximately half the death rate from breast cancer as those in the lowest.
High serum 25(OH)D was associated with lower mortality from breast cancer. Serum 25(OH)D in all patients with breast cancer should be restored to the normal range (30-80 ng/ml), with appropriate monitoring. Clinical or field studies should be initiated to confirm that this association was not due to reverse causation.
背景/目的：确定诊断时血清 25-羟维生素 D [25(OH)D]水平较高是否与乳腺癌患者的生存时间延长有关。
对五项研究进行了荟萃分析，这些研究评估了 25(OH)D 与乳腺癌死亡率之间的关系。使用随机效应模型计算了合并的风险比。采用德西蒙尼-莱尔德检验评估同质性。
较高的血清 25(OH)D 浓度与乳腺癌诊断后较低的病死率相关。具体而言，25(OH)D 最高五分位的患者的乳腺癌死亡率约为最低五分位的一半。
高血清 25(OH)D 与乳腺癌死亡率降低相关。所有乳腺癌患者的血清 25(OH)D 应恢复到正常范围（30-80ng/ml），并进行适当监测。应开展临床或现场研究以确认这种关联不是由于反向因果关系造成的。
